Stay updated with breaking news from Robert Steinbrook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The changes in coverage for millions of Americans, already underway, could derail treatment plans for the most vulnerable patients being treated for opioid use disorder, providers and public health experts told POLITICO.
From today through the end of September, the FDA has scheduled seven meetings of its expert panels, none of which will be in person.
The Alzheimer's drug's approval would trigger broader access under Medicare, but critics say it shouldn't be on the market at all.
The share of money heading towards lobbying activities on Capitol Hill is increasingly coming from healthcare companies. The ...
The estimated savings to Medicare during 2015-2020 that resulted from competition with five of the first-to-market biosimilars with skinny labels was $1.5 billion.